Publicação científica trimestral do CREMERJ - volume 2 - número 2 - 2023

86 Tromboembolismo venoso no climatério André Luiz Malavasi Longo de Oliveira et al. Med. Ciên. e Arte , Rio de Janeiro, v.2, n.2, p.77-86, abr-jun 2023 21. Canonico M, et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study. Circulation. 2007;115(7):840-5. 22. Canonico M, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010a;30(2):340-5. 23. Renoux C, et al. Hormone replacement therapy and the risk of venous thromboembolism: a population- based study. J Thromb Haemost. 2010;8(5):979-86. 24. Sweetland S, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-86. 25. Roach REJ, et al. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost. 2013;11(1):124-31. 26. Olié V, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488-93. 27. Scarabin P-Y, et al. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause. 2011;18(8):873-9. 28. Oger E. Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671-6. 29. Scarabin P-Y, et al. Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women: A Randomized Controlled Trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071-8. 30. Canonico M, et al. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause. 2010b;17(6):1122-7. 31. Tremollieres F, et al. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas. 2011;69(2):195-8. 32. North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012;19(3):257-71.